Elanco Animal Health Incorporated (ELAN) on Tuesday said that the U.S. Food and Drug Administration (FDA) has approved an updated label for its Zenrelia, removing language related to vaccine-induced disease.
Zenrelia, approved by the FDA in September last year, is indicated for controlling itching and inflammation caused by skin allergies in dogs aged 12 months and older. At launch, the U.S. Zenrelia label included warnings based on a laboratory study where unvaccinated dogs were given three times the recommended dose. An outbreak of other illnesses during the study made the results hard to interpret.
After reviewing additional data, the FDA concluded that the overall evidence supports removing the warning about fatal vaccine-induced disease from modified live virus vaccines. This language has now been removed from the U.S. Zenrelia label.
However, the label's Boxed Warning continues to advise discontinuing Zenrelia at least 28 days to 3 months prior to vaccination and withholding it for at least 28 days after vaccination, due to the risk of a reduced immune response.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.